CD133-specific CAR-T cell therapy / Century Therap - LARVOL DELTA

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID)... Century Therapeutics...today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in five posters at the 2024 ASH Annual Meeting to be held in San Diego, CA from December 7-10, 2024...This includes data relating to our enhanced Allo-Evasion via a novel CD300a TASR that demonstrated universal protection from NK cells, advanced CAR endo-domains that improve cytotoxicity and persistence, and differentiation-stage-specific promoters that allow for selective control of gene expression. Furthermore, we are encouraged by data demonstrating our CAR iNK and γδ iT cells’ potent preclinical ability to treat B-cell-mediated autoimmune diseases."

Preclinical • Immunology • Oncology

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "In this study, the Company showed that the combination of HLA-E and HLA-G expression was the most effective in protecting allogeneic drug products from elimination of genetically dissimilar cells. Investigators assessed allo-evasion from natural killer (NK) cells by iPSC-derived cells engineered to express HLA-E and -G. NK cells across donors expressed heterogeneous combinations of HLA-E and -G ligands. K562 and iPSC-derived cells lacking HLA-I were susceptible to killing by PBMCs. Overexpression of HLA-E and -G offered protection to K562 and iPSC-derived cells against all tested donors."

Preclinical • Oncology

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies (GlobeNewswire) - "Century Therapeutics...and Bristol Myers Squibb...announced today a research collaboration and license agreement (the 'agreement') to develop and commercialize up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell ('iNK') and / or T cell ('iT') programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform."

Licensing / partnership • Acute Myelogenous Leukemia • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor